Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States
As the First-To-File, Lupin is Eligible for 180-Day Generic Exclusivity MUMBAI, India and NAPLES, Fla., Nov. 3, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 116 stories mentioning NOV, the earliest published 25 Oct 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.